Concordance among three programmed death-ligand 1 (PD-L1) scoring methods and their association with clinical outcomes of tislelizumab (TIS) monotherapy in esophageal squamous cell carcinoma (ESCC).

被引：1
|
作者：
Shu, Yongqian
Wang, Jufeng
Chen, Zhendong
Kim, Sung-Bae
Lin, Chen-Yuan
Kato, Ken
Van Cutsem, Eric
Du, Wenting
Shi, Jingwen
Xia, Tianyu
Huang, Ruiqi
Li, Qiao
Zhang, Yun
Shen, Zhirong
Shen, Lin
机构：
[1] Nanjing Med Univ, Affiliated Hosp 1, Nanjing, Peoples R China
[2] Henan Canc Hosp, Zhengzhou, Peoples R China
[3] Anhui Med Hosp, Hosp 2, Hefei, Peoples R China
[4] Univ Ulsan, Asan Med Ctr, Coll Med, Seoul, South Korea
[5] China Med Univ Hosp, Taichung, Taiwan
[6] Natl Canc Ctr, Tokyo, Japan
[7] Univ Hosp Gasthuisberg Leuven, Leuven, Belgium
[8] Univ Leuven, Leuven, Belgium
[9] BeiGene Shanghai Co Ltd, Clin Biomarker, Shanghai, Peoples R China
[10] BeiGene Beijing Co Ltd, Clin Biomarker, Beijing, Peoples R China
[11] BeiGene Beijing Co Ltd, Stat, Beijing, Peoples R China
[12] BeiGene Beijing Co Ltd, Clin Dev, Beijing, Peoples R China
[13] Peking Univ Canc Hosp & Inst, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 3_SUPPL期
关键词：
3282-3306-2666-6279; 283-424-6846-271-2644; 613-135-2370-7650-2700; 11890-11879-11918-11863; 3282-206-3220-6287; 6; 5; 4; 1614; 2424; 3; 1; 38092-20072; 9;
D O I：
10.1200/JCO.2024.42.3_suppl.390
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：390 / 390
页数：1
相关论文
共 50 条
  • [1] ASSOCIATION BETWEEN PROGRAMMED DEATH-LIGAND 1 (PD-L1) EXPRESSION AND GENE SIGNATURES OF RESPONSE OR RESISTANCE TO TISLELIZUMAB MONOTHERAPY IN HEPATOCELLULAR CARCINOMA (HCC)
    Hou, Ming-Mo
    Rau, Kun-Ming
    Kang, Yoon-Koo
    Lee, Jong-Seok
    Pan, Hongming
    Yuan, Ying
    Yu, Cunjing
    Zhang, Yun
    Ma, Xiaopeng
    Wu, Xikun
    Li, Xin
    Wood, Katie
    Yen, Chia-Jui
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A47 - A48
  • [2] Programmed Cell Death-Ligand 1 (PD-L1) Expression in Oral Cavity Squamous Cell Carcinoma (OSCC)
    Satgunaseelan, Laveniya
    Madore, Jason
    Chia, Noel
    Lum, Trina
    Palme, Carsten E.
    Boyer, Michael
    Scolyer, Richard A.
    Clark, Jonathan R.
    Gupta, Ruta
    MODERN PATHOLOGY, 2016, 29 : 329A - 329A
  • [3] Programmed Cell Death-Ligand 1 (PD-L1) Expression in Oral Cavity Squamous Cell Carcinoma (OSCC)
    Satgunaseelan, Laveniya
    Madore, Jason
    Chia, Noel
    Lum, Trina
    Palme, Carsten E.
    Boyer, Michael
    Scolyer, Richard A.
    Clark, Jonathan R.
    Gupta, Ruta
    LABORATORY INVESTIGATION, 2016, 96 : 329A - 329A
  • [4] PROGRAMMED DEATH-LIGAND (PD-L1) EXPRESSION AND LYMPH NODE INVOLVEMENT IN PENILE SQUAMOUS CELL CARCINOMA
    Peyroteo, Ines
    Santos, Filipa
    JOURNAL OF UROLOGY, 2024, 211 (05): : E1010 - E1011
  • [5] Concordance of assessments of four PD-L1 immunohistochemical assays in esophageal squamous cell carcinoma (ESCC)
    Xinran Wang
    Jiankun He
    Jinze Li
    Chun Wu
    Meng Yue
    Shuyao Niu
    Ying Jia
    Zhanli Jia
    Lijing Cai
    Yueping Liu
    Journal of Cancer Research and Clinical Oncology, 150
  • [6] Concordance of assessments of four PD-L1 immunohistochemical assays in esophageal squamous cell carcinoma (ESCC)
    Wang, Xinran
    He, Jiankun
    Li, Jinze
    Wu, Chun
    Yue, Meng
    Niu, Shuyao
    Jia, Ying
    Jia, Zhanli
    Cai, Lijing
    Liu, Yueping
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2024, 150 (02)
  • [7] AdvanTIG-203: Phase II randomized, multicenter study of ociperlimab (OCI) plus tislelizumab (TIS) in patients (pts) with unresectable, locally advanced, recurrent/metastatic esophageal squamous cell carcinoma (ESCC) and programmed cell death-ligand 1 (PD-L1) positivity
    Wang, F.
    Lin, C-Y.
    Sun, J-M.
    Lu, C-H.
    Zhu, X.
    Chen, Z.
    Kim, I-H.
    Pan, Y.
    Zhang, J.
    Chen, Z.
    Tougeron, D.
    Kim, S-B.
    Van Cutsem, E.
    Abdrashitov, R.
    Ge, R.
    Sun, J.
    Zhou, J.
    Xu, R-H.
    ANNALS OF ONCOLOGY, 2023, 34 : S621 - S621
  • [8] Concordance among the three commercially available PD-L1 assays for esophageal squamous cell carcinoma
    Wang, Lizhen
    Guo, Jhe-Cyuan
    Chuang, Chien Huai
    Cao, Grace
    Huang, Stacey
    Liu, Jia
    Guo, Tony
    Wu, Tsung-Che
    Li, Shuang
    Lin, Jing
    King, Hsi-Yu
    Cai, Jun
    Yang, Wenjun
    Liu, Qingyuan
    Allen, Simon
    Wang, Yifan
    Zhang, Jingyu
    Hsu, Chih-Hung
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [9] Programmed death-ligand 1 (PD-L1) expression in pleomorphic carcinoma of the lung
    Imanishi, Naoko
    Hirai, Ayako
    Yoneda, Kazue
    Shimajiri, Shohei
    Kuwata, Taiji
    Tashima, Yuko
    Takeuchi, Masahiro
    Iwai, Yoshiko
    Ichiki, Yoshinobu
    Tanaka, Fumihiro
    JOURNAL OF SURGICAL ONCOLOGY, 2018, 117 (07) : 1563 - 1569
  • [10] Programmed death-ligand 1 (PD-L1) expression in small cell carcinoma of bladder.
    Sanguino, Angela
    Samiei, Arash
    Pasricha, Gurleen
    Harinath, Lakshmi
    Miller, Ralph
    Lyne, John
    Silverman, Jan F.
    Mao, Shifeng
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345